FGF21 and metabolic disease: Therefore, we suggest that CO acts as a potent mediator of metabolic homeostasis by increasing endogenous FGF21 expression, which may have therapeutic implications in nonalcoholic steatohepatitis, obesity, type 2 diabetes, and related metabolic disorders.